DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Biosimilar Substitution by State


Some states don’t have substitution laws--find out which ones.

Pharma and payers often disagree over how U.S. states should address substitutions of low-cost versions of biologic drugs.

Many states have already enacted laws dealing with substitution, but some markets have held out.

  • What are the “hurdles” biosimilar product substitution will face in the US?
  • Which states are lacking substitution laws?

DRG’s expert analysts have developed a NEW infographic to answer these questions.